Literature DB >> 29620794

Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation.

O O Moninuola1, W Milligan2, P Lochhead3, H Khalili3,4.   

Abstract

BACKGROUND: Unlike acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) have generally been thought to be associated with increased risk of IBD exacerbation. AIM: To carry out a systematic review and meta-analysis of previous studies examining the association between acetaminophen and NSAIDs including cyclooxygenase (COX-2) inhibitors use, and risk of Crohn's disease (CD) and ulcerative colitis (UC) exacerbation.
METHODS: We identified published manuscripts and abstracts through 1 March 2017 by systematic search of Medline, Embase, Cochrane and other trial registries. Quality assessment was done using Newcastle-Ottawa scale and random-effect meta-analysis using pooled relative risks (RRs) and 95% CIs were calculated.
RESULTS: Eighteen publications between years 1983 and 2016 were identified. For the meta-analysis, pooled RRs of disease exacerbation with NSAIDs use were (1.42, 95% CI, 0.65-3.09), I2  = 60.3% for CD, and (1.52, 95% CI, 0.87-2.63), I2  = 56.1% for UC. The corresponding values for acetaminophen use were (1.40, 95% CI, 0.96-2.04), I2  = 45.6% for UC, and (1.56, 95% CI, 1.22-1.99), I2  = 0.0% for IBD. Sensitivity analyses limited to studies with low risk of bias showed a significantly increased risk of CD exacerbation (1.53, 95% CI, 1.08-2.16) but not UC (0.94, 95% CI, 0.36-2.42) with NSAIDs use.
CONCLUSIONS: Contrary to generally accepted belief, we did not find a consistent association between NSAIDs use and risk of CD and UC exacerbation. There was also no consistent evidence for association with acetaminophen although further studies are needed.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29620794      PMCID: PMC5992031          DOI: 10.1111/apt.14606

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  44 in total

1.  Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study.

Authors:  J B Felder; B I Korelitz; R Rajapakse; S Schwarz; A P Horatagis; G Gleim
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

2.  Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: a case-control study.

Authors:  M H Gleeson; A J M Davis
Journal:  Aliment Pharmacol Ther       Date:  2003-03-15       Impact factor: 8.171

3.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

4.  Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.

Authors:  Uma Mahadevan; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

Review 5.  Non-steroidal anti-inflammatory drug gastropathy: causes and treatment.

Authors:  C J Hawkey
Journal:  Scand J Gastroenterol Suppl       Date:  1996

6.  The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.

Authors:  Yasser El Miedany; Sally Youssef; Ihab Ahmed; Maha El Gaafary
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

7.  The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease.

Authors:  Robin Matuk; Jonathan Crawford; Maria T Abreu; Stephan R Targan; Eric A Vasiliauskas; Konstantinos A Papadakis
Journal:  Inflamm Bowel Dis       Date:  2004-07       Impact factor: 5.325

Review 8.  Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers.

Authors:  C Musumba; D M Pritchard; M Pirmohamed
Journal:  Aliment Pharmacol Ther       Date:  2009-07-03       Impact factor: 8.171

9.  Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial.

Authors:  L Biancone; C Tosti; A Geremia; D Fina; C Petruzziello; S Emerenziani; F Pallone
Journal:  Aliment Pharmacol Ther       Date:  2004-04-01       Impact factor: 8.171

10.  A suggestion for quality assessment in systematic reviews of observational studies in nutritional epidemiology.

Authors:  Jong-Myon Bae
Journal:  Epidemiol Health       Date:  2016-04-26
View more
  8 in total

Review 1.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

Review 2.  Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.

Authors:  Hiroshi Nakase; Motoi Uchino; Shinichiro Shinzaki; Minoru Matsuura; Katsuyoshi Matsuoka; Taku Kobayashi; Masayuki Saruta; Fumihito Hirai; Keisuke Hata; Sakiko Hiraoka; Motohiro Esaki; Ken Sugimoto; Toshimitsu Fuji; Kenji Watanabe; Shiro Nakamura; Nagamu Inoue; Toshiyuki Itoh; Makoto Naganuma; Tadakazu Hisamatsu; Mamoru Watanabe; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-04-22       Impact factor: 7.527

3.  Expanding the drug discovery space with predicted metabolite-target interactions.

Authors:  Andrea Nuzzo; Somdutta Saha; Ellen Berg; Channa Jayawickreme; Joel Tocker; James R Brown
Journal:  Commun Biol       Date:  2021-03-05

4.  Do NSAIDs Take Us Away From Treatment Goals in Axial Spondyloarthritis: A Story About Dysbiosis or Just a Matter of Bias?

Authors:  Rubén Queiro-Silva; Andrea García-Valle; Sara Alonso-Castro; Mercedes Alperi-López
Journal:  Front Med (Lausanne)       Date:  2021-12-24

Review 5.  Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering.

Authors:  Jayshree Mishra; Madyson Stubbs; Longxiang Kuang; Nitza Vara; Priyam Kumar; Narendra Kumar
Journal:  Mediators Inflamm       Date:  2022-01-17       Impact factor: 4.711

6.  A systematic review and functional bioinformatics analysis of genes associated with Crohn's disease identify more than 120 related genes.

Authors:  Debora Garza-Hernandez; Maricruz Sepulveda-Villegas; Jose Garcia-Pelaez; Raul Aguirre-Gamboa; Peter L Lakatos; Karol Estrada; Manuel Martinez-Vazquez; Victor Trevino
Journal:  BMC Genomics       Date:  2022-04-13       Impact factor: 3.969

7.  Mass Spectrometric Identification of Licania rigida Benth Leaf Extracts and Evaluation of Their Therapeutic Effects on Lipopolysaccharide-Induced Inflammatory Response.

Authors:  Thayse Evellyn Silva do Nascimento; Jorge A López; Eder Alves Barbosa; Marcela Abbott Galvão Ururahy; Adriana da Silva Brito; Gabriel Araujo-Silva; Jefferson Romáryo Duarte da Luz; Maria das Graças Almeida
Journal:  Molecules       Date:  2022-09-23       Impact factor: 4.927

Review 8.  Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes.

Authors:  Fenna M Jansen; Stephan R Vavricka; Alfons A den Broeder; Elke Mgj de Jong; Frank Hoentjen; Willemijn A van Dop
Journal:  United European Gastroenterol J       Date:  2020-09-14       Impact factor: 4.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.